Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system. The result is a compensatory, often exaggerated and chronic inflammatory response by less effective alternative immune pathways, which damage not only infected cells but also surrounding tissue.
This report provides the current prevalent population for PID across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Sweden, Austria, Switzerland, Greece, Czech Republic, Hungary, Turkey, Japan, China, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher's analysis team, PID patients grouped by disease classification have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for PID include:
Severe Congenital Immunodeficiency (SCID)
Recurrent or persistent infections
Allergic manifestations
Respiratory diseases
Organ problems
Developmental delay
Reasons to buy
Ability to quantify patient populations in global PID market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of PID and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Identification of PID patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of PID patients.
Key Topics Covered:
Introduction
Cause Of The Disease
Risk Factors & Prevention
Diagnosis Of The Disease
Variation By Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With The Disease
Methodology For Quantification Of Patient Numbers
Top-Line Prevalence For Primary Immunodeficiency Diseases
Features Of Primary Immunodeficiency Diseases Patients
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...